 |
AI For Pharma GrowthAuthor: Dr Andree Bates
AI For Pharma Growth is the podcast from pioneering Artificial Intelligence entrepreneur Dr. Andree Bates created to help Pharma, Biotech and other Healthcare companies understand how the use of AI-based technologies can easily save them time and grow their brands and company results. This show blends deep experience in the sector with demystifying AI for biopharma execs from biotech start-ups right through to big pharma. In this podcast, Dr Andree will teach you the tried and true secrets to building results in a pharma company using AI and alert you to some fascinating new tools and applications to benefit you and your company. As the author of many peer-reviewed journals in pharma AI, and having addressed over 500 industry conferences across the globe, Dr Andree Bates uses her obsession with all things AI, futuretech, healthcare and pharma to help you to navigate through the, sometimes confusing, but magical world of AI powered tools to achieve real-world results. This podcast features many experts who have developed powerful AI-powered tools that are the secret behind some time-saving and supercharged revenue-generating business results. Those who share their stories and expertise show how AI can be applied to Discovery, R&D, clinical trials, market access, medical affairs, regulatory, market research, business insights, sales, marketing, including digital marketing, and so much more. Language: en Genres: Science, Technology Contact email: Get it Feed URL: Get it iTunes ID: Get it |
Listen Now...
E216: When AI meets Cell Engineering
Episode 216
Tuesday, 5 May, 2026
Cell therapies have huge potential, but cost, complexity, and centralised manufacturing have kept many of them confined to last-line use. In this episode, Dr Andree Bates speaks with Armon Sharei, Founder and CEO of Portal Biotechnologies, about what happens when AI meets cell engineering, and why point-of-care delivery could make personalised cell programming more practical, scalable, and safer.Armon explains Portal’s core idea: cells are programmable machines. If you can reliably deliver multiple cargoes into cells, you can instruct new behaviours. Portal’s method briefly “squishes” cells through precision pores to disrupt the membrane so external material can enter, opening the door to complex cell engineering without permanent genome edits.They explore where AI fits in: modelling cell behaviour. By combining perturbation experiments, rich readouts, and phenotypic screening, AI can help generate “virtual cell models” that suggest which RNA instructions to deliver to drive specific outcomes. The bottleneck is data at the right complexity, because many effects only appear when multiple pathways are changed at once.A key takeaway is the safety and flexibility of transient RNA reprogramming. Unlike irreversible genetic modification, RNA fades within days, reducing long-term risk and making earlier-line use more realistic. Armon also discusses how point-of-care workflows may be regulated differently, with the machine treated as a device and the cargo as the drug.Looking ahead, he paints a vision of infusion-centre cell programming: a compact system that takes blood, delivers tailored RNA instructions to immune cells, and returns them within hours, potentially bringing costs closer to mainstream biologics and expanding access.Topics CoveredWhy delivery is the unlock for programmable cell therapiesHow Portal’s “cell squishing” delivery worksUsing AI to model cells and generate functional programmesThe data bottleneck and why multi-perturbation datasets matterPhenotypic screening and lab-to-clinic feedback loopsTransient RNA reprogramming vs permanent genetic modificationRegulatory implications of point-of-care engineeringEconomics and scalability of point-of-care approachesNear-term opportunities in oncology and autoimmunityThe future vision for infusion-centre personalised therapiesEularis helps pharma and biotech leaders turn AI activity into board-defensible strategy and measurable commercial outcomes.If your organisation has plenty of AI in motion but very little that moves the commercial needle in a way the board can see, start with our 10-Day AI Diagnostic Sprint. It’s a focused diagnostic that surfaces what’s actually broken and what’s blocking results, before you invest in a larger strategy effort.The Sprint diagnoses the problem. The AI Strategic Blueprint that follows is where we build the board-defensible strategy and plan.Details at eularis.com.About the PodcastAI For Pharma Growth is the podcast from pioneering Pharma Artificial Intelligence entrepreneur Dr Andree Bates, created to help pharma, biotech and healthcare organisations understand how AI-based technologies can save time, grow brands, and improve company results.This show blends deep sector experience with practical conversations that demystify AI for biopharma leaders, from start-up biotech right through to Big Pharma. Each episode features experts building AI-powered tools that are driving real-world results across discovery, R&D, clinical trials, medical affairs, market access, regulatory, insights, sales, marketing, and more.AI platforms and tools solve specific problems. Strategy makes sure you’re solving the right ones, in the right order. If you want help mapping priorities as you evaluate what to roll out next, send me a LinkedIn DM starting with ‘PRIORITIES’ and two lines: what’s already in flight, and the decision you’re trying to make next.Dr. Andree Bates LinkedIn | Facebook | X
